CpG-specific methylation at rheumatoid arthritis diagnosis as a marker of treatment response

Epigenomics. 2017 May;9(5):595-597. doi: 10.2217/epi-2017-0011. Epub 2017 Apr 27.

Authors

Steven Horsburgh¹, Marzena Ciechomska², Steven O'Reilly¹

Affiliations

¹ Department of Applied Sciences, Northumbria University, Newcastle upon Tyne, UK.
² National Institute of Geriatrics, Rheumatology & Rehabilitation, Warsaw, Poland.

PMID: 28447857
DOI: 10.2217/epi-2017-0011

No abstract available

Keywords: DMARDs; DNA methylation; T lymphocytes.

Publication types

Editorial

MeSH terms

ADAMTS Proteins / genetics
ADAMTS Proteins / metabolism*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / diagnosis
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / genetics
Arthritis, Rheumatoid / metabolism
Biomarkers / metabolism
Butyrophilins / genetics
Butyrophilins / metabolism*
CpG Islands
DNA Methylation / drug effects*
Epigenesis, Genetic*
Fibroblasts / drug effects
Fibroblasts / metabolism
Fibroblasts / pathology
Humans
Hydroxychloroquine / therapeutic use
Joint Capsule / drug effects
Joint Capsule / metabolism
Joint Capsule / pathology
Methotrexate / therapeutic use
Sulfasalazine / therapeutic use
T-Lymphocytes / drug effects
T-Lymphocytes / metabolism
T-Lymphocytes / pathology

Substances

Antirheumatic Agents
BTN3A2 protein, human
Biomarkers
Butyrophilins
Sulfasalazine
Hydroxychloroquine
ADAMTS Proteins
ADAMTSL2 protein, human
Methotrexate